Search results
Showing 16 to 18 of 18 results for eculizumab
guidelines . 2015 First highly specialised technologies guidance HST1 Eculizumab for treating atypical haemolytic uraemic syndrome...
Hundreds of people with a rare blood disorder have access to a new treatment regimen following draft guidance from NICE.
Patients with rare blood disorders to receive new treatment option, says NICE
In final guidance published today (20 May 2021), NICE has recommended ravulizumab (Ultomiris, Alexion Pharmaceuticals) as a treatment for paroxysmal nocturnal haemoglobinuria (PNH). Draft guidance published 19 May 2021 also recommends the treatment for atypical haemolytic uraemic syndrome (aHUS).